Our studies identify HELLS as an important regulator of the BER/SSBR pathway, which could serve as a potential therapeutic target in the sensitization of cancer cells to alkylation chemotherapy and PARPi, especially in the context of HR deficiency. Here, HELLS is linked to cancer.